Back to Search Start Over

Safety and Efficacy of Buccal Dexmedetomidine for MRI Sedation in School-Aged Children.

Authors :
Boriosi JP
Eickhoff JC
Hollman GA
Source :
Hospital pediatrics [Hosp Pediatr] 2019 May; Vol. 9 (5), pp. 348-354. Date of Electronic Publication: 2019 Apr 10.
Publication Year :
2019

Abstract

Objectives: Intranasal, intramuscular, and intravenous (IV) dexmedetomidine routes have been used successfully for pediatric MRI studies. We designed this retrospective study to determine efficacy and safety of buccal dexmedetomidine for pediatric MRI sedation.<br />Methods: Medical records were reviewed of outpatient children ages 5 to 18 years who received buccal dexmedetomidine with or without oral midazolam for MRI sedation at a freestanding children's hospital sedation program in 2015 and 2016.<br />Results: A total of 220 outpatient encounters received buccal dexmedetomidine for MRI. Mean age of the cohort was 10.1 ± 2.6 years (range: 5-18.7). Buccal dexmedetomidine dose administered was a mean of 2.20 ± 0.38 μg/kg (range: 0.88-3.19). Of the 220 sedation encounters, 179 (81.4%) patients had satisfactory sedation with buccal dexmedetomidine with or without oral midazolam: 84 had buccal dexmedetomidine as the sole sedative, 95 had satisfactory sedation when buccal dexmedetomidine and oral midazolam (mean: 0.33 ± 0.07 mg/kg; range: 0.21-0.53) were given together, 1 (0.4%) had satisfactory sedation when intranasal fentanyl and midazolam were administered in addition to buccal dexmedetomidine, and 35 (15.9%) required IV sedatives to achieve satisfactory sedation. All patients completed their MRI successfully except 5 (2.2%): 2 encounters were sedation failures, 2 IV sedations developed severe upper airway obstruction, and 1 IV sedation experienced MRI contrast anaphylaxis.<br />Conclusions: In a selected population of pediatric patients, buccal dexmedetomidine with or without midazolam provides adequate sedation for most MRI studies with few adverse effects, but given a failure rate of almost 20%, modifications to buccal dexmedetomidine dosing should be investigated.<br />Competing Interests: POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.<br /> (Copyright © 2019 by the American Academy of Pediatrics.)

Details

Language :
English
ISSN :
2154-1671
Volume :
9
Issue :
5
Database :
MEDLINE
Journal :
Hospital pediatrics
Publication Type :
Academic Journal
Accession number :
30971402
Full Text :
https://doi.org/10.1542/hpeds.2018-0162